TY - JOUR
T1 - Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors
AU - Sonbol, Mohamad Bassam
AU - Halfdanarson, Thorvardur R.
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.
AB - In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.
KW - High-grade
KW - Neuroendocrine carcinoma
KW - Neuroendocrine neoplasm
KW - Neuroendocrine tumor
KW - PRRT
UR - http://www.scopus.com/inward/record.url?scp=85070985520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070985520&partnerID=8YFLogxK
U2 - 10.1007/s11864-019-0670-1
DO - 10.1007/s11864-019-0670-1
M3 - Review article
C2 - 31428952
AN - SCOPUS:85070985520
SN - 1527-2729
VL - 20
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 9
M1 - 74
ER -